Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience

Cantiello, Francesco; Gangemi, Vincenzo; Cascini, Giuseppe Lucio; Calabria, Ferdinando; Moschini, Marco; Ferro, Matteo; Musi, Gennaro; Butticè, Salvatore; Salonia, Andrea; Briganti, Alberto; Damiano, Rocco

doi:10.1016/j.urology.2017.04.019

Cited by 43 publications

(37 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Remaining 35 full-text articles were assessed for eligibility and 28 articles were excluded due to insufficient data (23 studies) for the calculation of sensitivity and specificity of PSMA PET or PET/CT for primary LN staging in newly diagnosed intermediate to high-risk PCa patients and 1 non-English article. Finally, 6 studies were selected and were eligible for the systematic review and meta-analysis and no additional studies were found screening the references of these articles [17][18][19][20][21][22]. The characteristics of the included studies are presented in Table 1.…”

Section: Literature Search and Selection Of Studiesmentioning

confidence: 99%

“…Among those 4 studies included in the current review, 9 studies conducted patient-based analysis of radiolabeled PSMA PET/CT [17,[19][20][21]. Other 2 studies included both patient and lesionbased analysis [18,22].…”

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

“…There was a total of 298 patients and 251 lesions in the included studies, and the age ranged from 44 to 80 years. Of all 6 studies, 3 studies enrolled patients retrospectively [17][18][19]; other 3 studies [20][21][22] enrolled patients prospectively. Four studies [17][18][19][20] used PET/CT, one study [21] used PET/CT and PET/ MRI, and another study [22] used PET as imaging device in their studies.…”

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

“…Several previous studies have evaluated and shown a high diagnostic performance of Ga-68 PSMA PET/CT in the detection of local and distant disease, with a higher sensitivity compared to other radiopharmaceuticals such as radiolabeled choline [12][13][14][15][16]. However, few studies investigated the diagnostic performance of radiolabeled PSMA for primary LN staging in newly diagnosed, intermediate to high-risk PCa patients with various sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) [17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis

Kim

Lee

2018

Urol Int

View full text Add to dashboard Cite

Introduction: We aimed to assess the diagnostic accuracy of radiolabeled prostate-specific membrane antigen positron emission tomography (PSMA PET) or positron emission tomography/computed tomography (PET/CT) for primary lymph node (LN) staging in newly diagnosed intermediate to high-risk prostate cancer (PCa) patients. Material and Methods: The MEDLINE, PubMed, EMBASE, and Cochrane Library database from the earliest available date of indexing through May 31, 2018, were searched for studies evaluating the diagnostic performance of radiolabeled PSMA PET or PET/CT for primary LN staging in newly diagnosed intermediate to high-risk PCa. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR–), and constructed summary receiver operating characteristic curves. Results: Across 6 studies (298 patients), the pooled sensitivity was 0.71 (95% CI 0.59–0.81) and a pooled specificity of 0.95 (95% CI 0.87–0.99). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 15.6 (95% CI 5.6–43.0) and negative likelihood ratio (LR–) of 0.30 (95% CI 0.21–0.43). The pooled diagnostic odds ratio (DOR) was 51 (95% CI 21–126). Conclusion: Radiolabeled PSMA PET/CT shows a moderate sensitivity and high specificity for the detection of metastatic LNs in patients with newly diagnosed intermediate to high-risk PCa.

show abstract

Section: Literature Search and Selection Of Studiesmentioning

confidence: 99%

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

Section: Study Description Quality and Publication Biasmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis

Kim

Lee

2018

Urol Int

View full text Add to dashboard Cite

show abstract

“…CuCl 2 is a radio-pharmaceutical form used as a precursor for the in vitro radiolabeling of specific carriers, such as monoclonal antibodies, peptides, aminoacids, hormones and other molecules for PET imaging and/or for radionuclide therapy [2,14,15]. In several studies copper-64 was used in association with other therapeutic regimens in an attempt to overcome cross-resistance phenomena also dependent on Cu metabolism in tumor cells.…”

mentioning

confidence: 99%

The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells

Catalogna

Talarico

Dattilo

et al. 2017

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: The importance of copper in the metabolism of cancer cells has been widely studied in the last 20 years and a clear-cut association between copper levels and cancer deregulation has been established. Copper-64, emitting positrons and β-radiations, is indicated for the labeling of a large number of molecules suitable for radionuclide imaging as well as radionuclide therapy. Glioblastoma multiforme (GBM) is the CNS tumor with the worse prognosis, characterized by high number of recurrences and strong resistance to chemo-radio therapy, strongly affecting patients survival. We have recently discovered and studied the small molecule SI113, as inhibitor of SGK1, a serine/threonine protein kinase, that affects several neoplastic phenotypes and signaling cascades. The SI113-dependent SGK1 inhibition induces cell death, blocks proliferation, perturbs cell cycle progression and restores chemoradio sensibility by modulating SGK1-related substrates. In the present paper we aim to characterize the combined effects of 64 CuCl 2 and SI113 on human GBM cell lines with variable p53 expression. Methods: Cell viability, cell death and stress/authopagic related pathways were then analyzed by FACS and WB-based assays, after exposure to SI113 and/or 64 CuCl 2 . Results: We demonstrate here, that i) 64 CuCl 2 is able to induce a time and dose dependent modulation of cell viability (with different IC 50 values) in highly malignant gliomas and that the co-treatment with SI113 leads to ii) additive/synergistic effects in terms of cell death; iii) enhancement of the effects of ionizing radiations, probably by a TRC1 modulation; iv) modulation of the autophagic response. Conclusions: Evidence reported here underlines the therapeutic potential of the combined treatment with SI113 and 64 CuCl 2 in GBM cells.G. Catalogna and C. Talarico equally contributed to this work.

show abstract

Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer

et al. 2021

View full text Add to dashboard Cite

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic applications. The imaging modalities positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are based on γ-emissions of specific energies. The therapeutic technologies are based on β À -particle-, α-particle-, and Auger electron emitters. In oncology, PET and SPECT are used to detect cancer lesions, to determine dosimetry, and to monitor therapy effectiveness. In contrast, radiotherapy is designed to irreparably damage tumor cells in order to eradicate or control the disease's progression. Radiometals are being explored for the development of diagnostic and therapeutic radiopharmaceuticals. Strategies that combine both modalities (diagnostic and therapeutic), referred to as theranostics, are promising candidates for clinical applications. This review provides an overview of the basic concepts behind therapeutic and diagnostic radiopharmaceuticals and their significance in contemporary oncology. Select radiometals that significantly impact current and upcoming cancer treatment strategies are grouped as clinically suitable theranostics pairs. The most important physical and chemical properties are discussed. Standard production methods and current radionuclide availability are provided to indicate whether a cost-efficient use in a clinical routine is feasible. Recent preclinical and clinical developments and outline perspectives for the radiometals are highlighted in each section.

show abstract

Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience

Cited by 43 publications

References 29 publications

Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis

Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis

The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells

Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer

Contact Info

Product

Resources

About